Apo A-IMilano is a mutant form of apo A-I in which cysteine is substituted for arginine at amino acid 173. Subjects with apo A-IMilano are characterized by having low levels of plasma HDL cholesterol and apo A-I. To determine the kinetic etiology of the decreased plasma levels of the apo A-I in these individuals, normal and mutant apo A-I were isolated, radiolabeled with either 125I or 131I, and both types of apo A-I were simultaneously injected into two normal control subjects and two subjects heterozygous for apo A-IMilano. In the normal subjects, apo A-IMilano was catabolized more rapidly than the normal apo A-I (mean residence times of 5.11 d for normal apo A-I vs. 3.91 d for apo A-IMilano), clearly establishing that apo A-IMilano is kinetically abnormal and that it has a shortened residence time in plasma. In the two apo A-IMilano subjects, both types of apo A-I were catabolized more rapidly than normal (residence times ranging from 2.63 to 3.70 d) with normal total apo A-I production rates (mean of 10.3 vs. 10.4 mg/kg per d in the normal subjects). Therefore, in the subjects with apo A-IMilano, the decreased apo A-I levels are caused by rapid catabolism of apo A-I and not to a decreased production rate, and the abnormal apo A-IMilano leads to the rapid catabolism of both the normal and mutant forms of apo A-I in the affected subjects.
P Roma, R E Gregg, M S Meng, R Ronan, L A Zech, G Franceschini, C R Sirtori, H B Brewer Jr
Title and authors | Publication | Year |
---|---|---|
HDL-replacement therapy: From traditional to emerging clinical applications
Sirtori CR, Cincotto G, Castiglione S, Pavanello C |
Atherosclerosis Plus | 2025 |
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.
Kalayci A, Gibson CM, Ridker PM, Wright SD, Kingwell BA, Korjian S, Chi G, Lee JJ, Tricoci P, Kazmi SH, Fitzgerald C, Shaunik A, Berman G, Duffy D, Libby P |
Current Atherosclerosis Reports | 2022 |
Apolipoproteins in vascular biology and atherosclerotic disease
A Mehta, MD Shapiro |
Nature Reviews Cardiology | 2021 |
Lipid efflux mechanisms, relation to disease and potential therapeutic aspects
D Castaño, C Rattanasopa, VF Monteiro-Cardoso, M Corlianò, Y Liu, S Zhong, M Rusu, EA Liehn, RR Singaraja |
Advanced Drug Delivery Reviews | 2020 |
Nascent HDL (High-Density Lipoprotein) Discs Carry Cholesterol to HDL Spheres: Effects of HDL Particle Remodeling on Cholesterol Efflux
AV Navdaev, L Sborgi, SD Wright, SA Didichenko |
Arteriosclerosis, thrombosis, and vascular biology | 2020 |
Is HDL cholesterol protective in patients with type 2 diabetes? A retrospective population-based cohort study
G Fanni, R Rosato, L Gentile, M Anselmino, S Frea, V Ponzo, M Pellegrini, F Broglio, F Pivari, GM Ferrari, E Ghigo, S Bo |
Journal of Translational Medicine | 2020 |
HDL therapy today: from atherosclerosis, to stent compatibility to heart failure
CR Sirtori, M Ruscica, L Calabresi, G Chiesa, R Giovannoni, JJ Badimon |
Annals of Medicine | 2019 |
The role of paraoxonase 1 in regulating high-density lipoprotein functionality during aging
A Khalil, OK Simo, S Ikhlef, H Berrougui |
Canadian Journal of Physiology and Pharmacology | 2017 |
ApoA-IMilano phospholipid complex (ETC-216) infusion in human volunteers. Insights into the phenotypic characteristics of ApoA-IMilano carriers
CL Bisgaier, R Ackermann, T Rea, WV Rodrigueza, D Hartman |
Pharmacological Research | 2016 |
ApoA-I-Directed Therapies for the Management of Atherosclerosis
JS Millar, M Cuchel |
Current Atherosclerosis Reports | 2015 |
High-density lipoprotein mimetics: promises and challenges
D Sviridov, AT Remaley |
Biochemical Journal | 2015 |
HDL quality and functionality: what can proteins and genes predict?
EA Karavia, E Zvintzou, PI Petropoulou, E Xepapadaki, C Constantinou, KE Kypreos |
Expert Review of Cardiovascular Therapy | 2014 |
A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production
P Anthanont, E Polisecki, BF Asztalos, MR Diffenderfer, PH Barrett, JS Millar, J Billheimer, M Cuchel, DJ Rader, EJ Schaefer |
Atherosclerosis | 2014 |
HDL and atherosclerosis: Insights from inherited HDL disorders
L Calabresi, M Gomaraschi, S Simonelli, F Bernini, G Franceschini |
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | 2014 |
Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys
HJ Kempen, M Gomaraschi, SE Bellibas, S Plassmann, B Zerler, HL Collins, SJ Adelman, L Calabresi, PL Wijngaard |
Journal of lipid research | 2013 |
HDL and endothelial protection: examining evidence from HDL inherited disorders
M Gomaraschi, A Ossoli, C Vitali, L Calabresi |
Clinical Lipidology | 2013 |
Reconstituted HDL for the acute treatment of acute coronary syndrome:
BR Krause, AT Remaley |
Current Opinion in Lipidology | 2013 |
Structural basis for distinct functions of the naturally occurring Cys mutants of human apolipoprotein A-I
O Gursky, MK Jones, X Mei, JP Segrest, D Atkinson |
Journal of lipid research | 2013 |
High Density Lipoprotein: Assembly, Structure, Cargo, and Functions
AJ Murphy |
ISRN Physiology | 2013 |
Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys[S]
HJ Kempen, M Gomaraschi, SE Bellibas, S Plassmann, B Zerler, HL Collins, SJ Adelman, L Calabresi, PL Wijngaard |
Journal of lipid research | 2013 |
Recombinant high-density lipoprotein nanoparticles containing gadolinium-labeled cholesterol for morphologic and functional magnetic resonance imaging of the liver
M Rui, W Guo, Q Ding, X Wei, J Xu, Y Xu |
International Journal of Nanomedicine | 2012 |
Lipoproteins as biosensors of endothelial oxidative status
M Farkas-Epperson, NA Le |
Clinical Lipidology | 2012 |
Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approach
ML Curti, P Jacob, MC Borges, MM Rogero, SR Ferreira |
Journal of Obesity | 2011 |
Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises
TA Ahmed, I Karalis, JW Jukema |
Expert Opinion on Emerging Drugs | 2011 |
Qualitative characteristics of HDL in young patients of an acute myocardial infarction
AE Kavo, LS Rallidis, GC Sakellaropoulos, S Lehr, S Hartwig, J Eckel, PI Bozatzi, M Anastasiou-Nana, P Tsikrika, KE Kypreos |
Atherosclerosis | 2011 |
Burger's Medicinal Chemistry and Drug Discovery
S Bruno, L Ronda, S Faggiano, S Bettati, A Mozzarelli |
Burger's Medicinal Chemistry and Drug Discovery | 2010 |
HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis
EM Tsompanidi, MS Brinkmeier, EH Fotiadou, SM Giakoumi, KE Kypreos |
Atherosclerosis | 2010 |
The HDL Handbook
NJ Hime |
The HDL Handbook | 2010 |
High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease
EJ Schaefer |
2010 | |
Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I
ET Alexander, M Tanaka, M Kono, H Saito, DJ Rader, MC Phillips |
Journal of lipid research | 2009 |
Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I
ET Alexander, M Tanaka, M Kono, H Saito, DJ Rader, MC Phillips |
Journal of lipid research | 2009 |
Can We Cause Regression of Coronary Atherosclerosis?
S Alsafwah, KB Ramanathan |
The American Journal of the Medical Sciences | 2008 |
Antiatherogenic Functionality of High Density Lipoprotein: How Much versus How Gooden-subtitle=
D Sviridov, N Mukhamedova, AT Remaley, J Chin-Dusting, P Nestel |
Journal of Atherosclerosis and Thrombosis | 2008 |
ApoA‐I Milano from structure to clinical application
I Eberini, E Gianazza, L Calabresi, CR Sirtori |
Annals of Medicine | 2008 |
Therapeutic Lipidology
MH Davidson, PP Toth, KC Maki, AM Gotto |
2008 | |
Wild-type apo A-I and apo A-IMilano gene transfer reduce native and transplant arteriosclerosis to a similar extent
Y Feng, EV Craeyveld, F Jacobs, J Lievens, J Snoeys, BD Geest |
Journal of Molecular Medicine | 2008 |
Genetic determinants of HDL: monogenic disorders and contributions to variation
KL Klos, IJ Kullo |
Current Opinion in Cardiology | 2007 |
Sources of variability of plasma HDL-cholesterol levels
M Bove, AF Cicero, M Manca, I Georgoulis, R Motta, L Incorvaia, M Giovannini, G Poggiopollini, AV Gaddi |
Future Lipidology | 2007 |
Human genetics of variation in high-density lipoprotein cholesterol
A Qasim, DJ Rader |
Current Atherosclerosis Reports | 2006 |
Lipids and the endothelium: an update
AJ Murphy, D Sviridov, JP Chin-Dusting |
Future Lipidology | 2006 |
A model structure for the heterodimer apoA-IMilano-apoA-II supports its peculiar susceptibility to proteolysis
AG Rocco, L Mollica, E Gianazza, L Calabresi, G Franceschini, CR Sirtori, I Eberini |
Biophysical Journal | 2006 |
Therapeutic use of the high-density lipoprotein protein and peptides
M Marchesi, CR Sirtori |
Expert Opinion on Investigational Drugs | 2006 |
Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans?: Fig. 1
S Rashid, BW Patterson, GF Lewis |
Journal of lipid research | 2006 |
Properties of ApoA-I Milano
CR Sirtori |
Nature Reviews Drug Discovery | 2005 |
Introduction to risk assessment and serum risk markers for the prevention of coronary heart disease and other potential conditions that impact men's health, part II: what do I tell my patients?
MA Moyad |
Urologic Clinics of North America | 2004 |
New frontiers in atherosclerosis prevention and treatment: HDL as a novel therapeutic target
CR Sirtori |
International Congress Series | 2004 |
Apolipoprotein A-I Milano and 1-Palmitoyl-2-oleoyl Phosphatidylcholine Complex (ETC-216) Protects the in Vivo Rabbit Heart from Regional Ischemia-Reperfusion Injury
M Marchesi, EA Booth, T Davis, CL Bisgaier, BR Lucchesi |
The Journal of pharmacology and experimental therapeutics | 2004 |
Apolipoprotein A-IMilano: current perspectives
G Chiesa, CR Sirtori |
Current Opinion in Lipidology | 2003 |
Recombinant apolipoprotein A-I[Formula: See Text]: a novel agent for the induction of regression of atherosclerotic plaques
G Chiesa, CR Sirtori |
Annals of Medicine | 2003 |
High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis
DJ Rader |
Journal of the American Medical Association | 2003 |
Thiol-bearing synthetic peptides retain the antioxidant activity of apolipoproteinA-IMilano
Z Jia, P Natarajan, TM Forte, JK Bielicki |
Biochemical and Biophysical Research Communications | 2002 |
Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks
G Chiesa, E Monteggia, M Marchesi, P Lorenzon, M Laucello, V Lorusso, CD Mario, E Karvouni, RS Newton, CL Bisgaier, G Franceschini, CR Sirtori |
Circulation research | 2002 |
Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-I Milano: EVIDENCE OF APOA-I M IMPAIRED HEPATIC SECRETION
C Parolini, G Chiesa, Y Zhu, T Forte, S Caligari, E Gianazza, MG Sacco, CR Sirtori, EM Rubin |
The Journal of biological chemistry | 2002 |
Apolipoprotein A-I Milano and Apolipoprotein A-I Paris Exhibit an Antioxidant Activity Distinct from That of Wild-Type Apolipoprotein A-I
JK Bielicki, MN Oda |
Biochemistry | 2002 |
ApoA-IMALLORCA impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia
JM Martín-Campos, J Julve, JC Escolà, J Ordóñez-Llanos, J Gómez, J Binimelis, F González-Sastre, F Blanco-Vaca |
Journal of lipid research | 2002 |
Enhanced fractional catabolic rate of apo A-I and apo A-II in heterozygous subjects for apo A-IZaragoza (L144R)
D Recalde, W Velez-Carrasco, F Civeira, A Cenarro, D Gomez-Coronado, JM Ordovas, M Pocovi |
Atherosclerosis | 2001 |
Cardiovascular Status of Carriers of the Apolipoprotein A-I Milano Mutant: The Limone sul Garda Study
CR Sirtori, L Calabresi, G Franceschini, D Baldassarre, M Amato, J Johansson, M Salvetti, C Monteduro, R Zulli, ML Muiesan, E Agabiti-Rosei |
Circulation | 2001 |
Cholesterol Mobilization by Free and Lipid-Bound ApoAI Milano and ApoAI Milano −ApoAII Heterodimers
WQ Wang, AS Moses, GA Francis |
Biochemistry | 2001 |
Limited proteolysis of a disulfide-linked apoA-I dimer in reconstituted HDL
L Calabresi, G Tedeschi, C Treu, S Ronchi, D Galbiati, S Airoldi, CR Sirtori, Y Marcel, G Franceschini |
Journal of lipid research | 2001 |
Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol
JD Kark, R Sinnreich, E Leitersdorf, Y Friedlander, S Shpitzen, G Luc |
Atherosclerosis | 2000 |
Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris
O Perez-Mendez, E Bruckert, G Franceschini, N Duhal, B Lacroix, JP Bonte, C Sirtori, JC Fruchart, G Turpin, G Luc |
Atherosclerosis | 2000 |
In Vivo Metabolism of HDL, Apo A-I, and Lp A-I, and Function of HDL -A Clinical Perspective
B Zhang, K Saku, T Ohta |
Journal of Atherosclerosis and Thrombosis | 2000 |
Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations
S Mott, L Yu, M Marcil, B Boucher, C Rondeau, J Genest Jr |
Atherosclerosis | 2000 |
Genes and Resistance to Disease
V Boulyjenkov, K Berg, Y Christen |
2000 | |
Apolipoprotein A-I: structure–function relationships
PG Frank, YL Marcel |
Journal of lipid research | 2000 |
Recombinant apolipoproteins for the treatment of vascular diseases
CR Sirtori, L Calabresi, G Franceschini |
Atherosclerosis | 1999 |
In vivo kinetics of human apolipoprotein A-I variants in rabbits
Saku, von Eckardstein, Zhang, Liu, Jimi, Ou, Ohta, Assmann, Arakawa |
European Journal of Clinical Investigation | 1999 |
A Novel Apolipoprotein A-1 Variant, Arg173Pro, Associated with Cardiac and Cutaneous Amyloidosis
KH Asl, JJ Liepnieks, M Nakamura, F Parker, MD Benson |
Biochemical and Biophysical Research Communications | 1999 |
Inhibition of arterial thrombus formation by ApoA1 Milano
D Li, S Weng, B Yang, DS Zander, T Saldeen, WW Nichols, S Khan, JL Mehta |
Arteriosclerosis, thrombosis, and vascular biology | 1999 |
A Novel Mutant, ApoA-I Nichinan (Glu235→0), Is Associated With Low HDL Cholesterol Levels and Decreased Cholesterol Efflux From Cells
H Han, J Sasaki, A Matsunaga, H Hakamata, W Huang, M Ageta, T Taguchi, T Koga, M Kugi, S Horiuchi, K Arakawa |
Arteriosclerosis, thrombosis, and vascular biology | 1999 |
Genetic influence on HDL cholesterol
DJ Betteridge, M Kahn |
The Lancet | 1998 |
Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein A-IMilano
G Chiesa, LJ Stoltzfus, S Michelagnoli, JK Bielicki, M Santi, TM Forte, CR Sirtori, G Franceschini, EM Rubin |
Atherosclerosis | 1998 |
Evaluation of Lipoproteins/Apolipoproteins as Therapeutic Agents for the Treatment of Vascular and Nonvascular Disease
CR Sirtori |
The American Journal of Cardiology | 1998 |
Lipoprotein-like Phospholipid Particles Inhibit the Smooth Muscle Cell Cytotoxicity of Lysophosphatidycholine and Platelet-Activating Factor
J Nilsson, B Dahlgren, M Ares, J Westman, AH Nilsson, B Cercek, PK Shah |
Arteriosclerosis, thrombosis, and vascular biology | 1998 |
A Novel Homozygous Missense Mutation in the Apo A-I Gene With Apo A-I Deficiency
W Huang, J Sasaki, A Matsunaga, H Nanimatsu, K Moriyama, H Han, M Kugi, T Koga, K Yamaguchi, K Arakawa |
Arteriosclerosis, thrombosis, and vascular biology | 1998 |
Familial HDL Deficiency Characterized by Hypercatabolism of Mature ApoA-I but Not ProApoA-I
R Batal, M Tremblay, L Krimbou, O Mamer, J Davignon, J Genest, JS Cohn |
Arteriosclerosis, thrombosis, and vascular biology | 1998 |
Apolipoprotein AI isoforms in serum determined by isoelectric focusing and immunoblotting
E Contiero, R Ferrari, GM Vaselli, M Folin |
Electrophoresis | 1997 |
In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107→0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency
M Tilly-Kiesi, CJ Packard, J Kahri, C Ehnholm, J Shepherd, MR Taskinen |
Atherosclerosis | 1997 |
The replacement of arginine by cysteine at residue 151 in Apolipoprotein A-I produces a phenotype similar to that of Apolipoprotein A-I Milano
E Bruckert, A Eckardstein, H Funke, I Beucler, H Wiebusch, G Turpin, G Assmann |
Atherosclerosis | 1997 |
Apolipoprotein A-I Fin: Dominantly Inherited Hypoalphalipoproteinemia Due to a Single Base Substitution in the Apolipoprotein A-I Gene
HE Miettinen, H Gylling, TA Miettinen, J Viikari, L Paulin, K Kontula |
Arteriosclerosis, thrombosis, and vascular biology | 1997 |
Subjects With ApoA-I(Lys 107 →0) Exhibit Enhanced Fractional Catabolic Rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI With AII)
M Tilly-Kiesi, AH Lichtenstein, JM Ordovas, G Dolnikowski, R Malmström, MR Taskinen, EJ Schaefer |
Arteriosclerosis, thrombosis, and vascular biology | 1997 |
Evidence That Apolipoprotein A-I Milano Has Reduced Capacity, Compared With Wild-Type Apolipoprotein A-I, to Recruit Membrane Cholesterol
JK Bielicki, MR McCall, LJ Stoltzfus, A Ravandi, A Kuksis, EM Rubin, TM Forte |
Arteriosclerosis, thrombosis, and vascular biology | 1997 |
Apolipoprotein A-I FIN (Leu159→Arg) Mutation Affects Lecithin: Cholesterol Acyltransferase Activation and Subclass Distribution of HDL but Not Cholesterol Efflux From Fibroblasts
HE Miettinen, M Jauhiainen, H Gylling, S Ehnholm, A Palomäki, TA Miettinen, K Kontula |
Arteriosclerosis, thrombosis, and vascular biology | 1997 |
Reconstituted High-Density Lipoproteins with a Disulfide-Linked Apolipoprotein A-I Dimer: Evidence for Restricted Particle Size Heterogeneity
L Calabresi, G Vecchio, F Frigerio, L Vavassori, CR Sirtori, G Franceschini |
Biochemistry | 1997 |
Human apolipoprotein A-II inhibits the formation of pre-β high density lipoproteins
L Calabresi, A Lucchini, G Vecchio, CR Sirtori, G Franceschini |
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | 1996 |
Compound Heterozygosity for a Structural Apolipoprotein A-I Variant, Apo A-I(L141R) Pisa , and an Apolipoprotein A-I Null Allele in Patients With Absence of HDL Cholesterol, Corneal Opacifications, and Coronary Heart Disease
R Miccoli, A Bertolotto, R Navalesi, L Odoguardi, A Boni, J Wessling, H Funke, H Wiebusch, A von Eckardstein, G Assmann |
Circulation | 1996 |
Drugs Affecting Lipid Metabolism
AM Gotto, R Paoletti, LC Smith, AL Catapano, AS Jackson |
1996 | |
New targets for lipid lowering and atherosclerosis prevention
CR Sirtori |
Pharmacology & Therapeutics | 1995 |
Microsomal enzyme inducers raise plasma high-density lipoprotein cholesterol levels in healthy control subjects but not in patients with primary hypoalphalipoproteinemia*
G Franceschini, JP Werba, AL D'Acquarica, G Gianfranceschi, S Michelagnoli, CR Sirtori |
Clinical Pharmacology & Therapeutics | 1995 |
Carboxyl-terminal Domain Truncation Alters Apolipoprotein A-I in Vivo Catabolism
HH Schmidt, AT Remaley, JA Stonik, R Ronan, A Wellmann, F Thomas, LA Zech, HB Brewer, JM Hoeg |
The Journal of biological chemistry | 1995 |
Recombinant Apolipoprotein A-I Milano Dimer Inhibits Carotid Intimal Thickening Induced by Perivascular Manipulation in Rabbits
MR Soma, E Donetti, C Parolini, CR Sirtori, R Fumagalli, G Franceschini |
Circulation research | 1995 |
Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits
S Ameli, A Hultgardh-Nilsson, B Cercek, PK Shah, JS Forrester, H Ageland, J Nilsson |
Circulation | 1994 |
In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism
K Ikewaki, DJ Rader, LA Zech, HB Brewer |
Journal of lipid research | 1994 |
Molecular characterization of native and recombinant apolipoprotein A-IMilano dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I
L Calabresi, G Vecchio, R Longhi, E Gianazza, G Palm, H Wadensten, A Hammarström, A Olsson, A Karlström, T Sejlitz |
The Journal of biological chemistry | 1994 |
Familial HDL deficiency due to marked hypercatabolism of normal apoA-I
J Emmerich, B Vergès, I Tauveron, D Rader, S Santamarina-Fojo, J Shaefer, M Ayrault-Jarrier, P Thiéblot, HB Brewer |
Arteriosclerosis Thrombosis and Vascular Biology | 1993 |